NCT06786208View on ClinicalTrials.gov

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Not yet recruitingOBSERVATIONAL

Enrollment

55

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2027

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Sunvozertinib

sunvozertinb, a EGFR-TKI, 300mg QD oral

Trial Locations (1)

450000

Qiming Wang, Zhengzhou

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV